Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1989-8-17
|
pubmed:abstractText |
The course of chronic hepatitis B was studied in 30 patients who had antibody to hepatitis e antigen and hepatitis B virus DNA in the serum and hepatitis B core antigen in the liver. Over a 2-year period, no patient experienced a sustained spontaneous remission of disease, and follow-up liver histology revealed worsening of the disease in four patients. After 2 years of observation, 24 patients were allocated randomly to one of two groups: 12 patients served as untreated controls and 12 received recombinant human alpha-interferon-2a in a dose of 9 million units intramuscularly three times weekly for 16 weeks. Patients who remained viremic after 16 weeks received 3 million units three times weekly for an additional 8 weeks. Abnormal amino-transferases and serum hepatitis B virus DNA persisted without appreciable changes in all untreated patients. Hepatitis B virus DNA rapidly became undetectable and serum aminotransferases fell to normal in eight treated patients. After the end of treatment, hepatitis B virus DNA became detectable once again in seven patients, in six of whom a peak of aminotransferases (range: 256 to 850 units per liter) ensued; subsequently, hepatitis B virus DNA disappeared, and serum aminotransferases again fell to normal in two of the seven. Overall, hepatitis B virus DNA was no longer detectable in serum and liver histology improved in three treated patients.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Alanine Transaminase,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B e Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin M,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon Type I
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0270-9139
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
10
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
198-202
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2663695-Adult,
pubmed-meshheading:2663695-Alanine Transaminase,
pubmed-meshheading:2663695-Chronic Disease,
pubmed-meshheading:2663695-Clinical Trials as Topic,
pubmed-meshheading:2663695-DNA, Viral,
pubmed-meshheading:2663695-Female,
pubmed-meshheading:2663695-Hepatitis B,
pubmed-meshheading:2663695-Hepatitis B Antibodies,
pubmed-meshheading:2663695-Hepatitis B e Antigens,
pubmed-meshheading:2663695-Hepatitis B virus,
pubmed-meshheading:2663695-Humans,
pubmed-meshheading:2663695-Immunoglobulin M,
pubmed-meshheading:2663695-Interferon Type I,
pubmed-meshheading:2663695-Male,
pubmed-meshheading:2663695-Middle Aged,
pubmed-meshheading:2663695-Prospective Studies,
pubmed-meshheading:2663695-Random Allocation
|
pubmed:year |
1989
|
pubmed:articleTitle |
Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen.
|
pubmed:affiliation |
Department of Gastroenterology, San Giovanni Battista Molinette Hospital, Turin, Italy.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|